Candidiasis – Pipeline Review, 2019

Candidiasis is a fungal infection caused by yeasts from the genus Candida. Candidiasis is majorly caused due to the Candida albicans. According to, Centers for Disease Control and Prevention estimated that approximately 46,000 cases of candidiasis occur each year in the U.S. Serval symptoms can be caused by the Candida infection, where vaginal and oral infections are among the most commonly occurring symptoms, while infections to the heart are among the rarest.

Currently various antibiotics such as clotrimazole, butoconazole, miconazole, and terconazole are approved by the U.S. Food and Drug Administration for the treatment of Candidiasis. Alternatively, an oral antifungal drug, fluconazole (Diflucan) can also be used for the treatment of the Candidiasis.

Research institutes and pharmaceutical companies are focussing on studying and developing new options for the treatment or prevention of candidiasis. For instance; SCY-078, which is being studied by Scynexis, Inc., is currently in phase-3 clinical trial for the study of assessment of the safety and efficacy of SCY-078 in patients with candidiasis caused by Candida Auris (CARES).

At present more than 30% of the pipeline candidates for candidiasis are in phase 3. Majority of the studies have been sponsored by pharmaceutical companies, along with few studies being sponsored by research institutes. 

Report Description

The report on ‘Candidiasis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Candidiasis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Candidiasis.

The report on ‘Candidiasis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players. 

Report Scope 

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases and relevant conferences 

Report Methodology 

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources includes global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases 

Reasons to Buy this Report 

• Develop effective growth strategies based on comprehensive overview of the R&D activity and pipeline products for Candidiasis
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Candidiasis
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary